Synaptic Vesicle Glycoprotein 2A (SV2A) CNS Drug Development: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epilepsy & Neurodegeneration Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SV2A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Purified, Detergent-Solubilized) | SV2A Full-Length Membrane Protein; HEK293 expressed, native glycosylation, >95% purity, endotoxin controlled. | View SV2A Products |
| Complex Membrane Target | SV2A Lentivirus Premade Particles; Full-length ORF (12-TMD) for stable cell lines. Sequence Verified. | View SV2A Products |
| Selectivity Panel | SV2B & SV2C Protein Panel; Paralog proteins for off-target binding assessment. High Purity (>95%), Endotoxin Controlled. | View SV2B Products |
| Cross-Species Toolkit | SV2A Ortholog Set (Human/Mouse/Cyno); For toxicology bridging studies. Theoretical MW verified. | View SV2A Products |
| Benchmark Antibody | Anti-SV2A (Levetiracetam Competing); Recombinant rabbit mAb for binding site mapping. Sequence Verified. | View SV2A Products |
| Functional Validator | SV2A siRNA Set; For knockdown verification in cell-based assays. | View SV2A Products |
| Pathway Partner | Synaptotagmin-1; Calcium sensor for synaptic vesicle release mechanism studies. | View Synaptotagmin-1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| 12-TMD Structure Requires Native Conformation | Lentivirus Stable Cell Lines (HEK293) preserving native membrane topology; Endotoxin <1 EU/µg |
| SV2 Family Selectivity (SV2B/C Off-target) | Homolog Panel Proteins strictly verified by Mass Spec; Human/SV2B/SV2C available |
| Cross-species CNS Penetration Bridging | Human/Mouse/Cyno ortholog proteins with Sequence Verified identity |
| Allosteric Binding Site Mapping | Cell-based binding assays using Full-Length Lentivirus constructs |
Live SV2A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The SV2A therapeutic landscape is transitioning from empirical small-molecule screening to rational modulation of synaptic vesicle dynamics. Major players are shifting focus from traditional antiepileptics (levetiracetam, brivaracetam) to advanced PET radiotracers for synaptic density mapping in neurodegenerative diseases. While first-generation ligands established SV2A as a validated anti-epileptic target, current R&D focuses on next-generation modulators with improved selectivity profiles and novel applications in neurodegeneration. The emergence of SV2A-targeted PET imaging agents for Alzheimer's disease diagnosis represents a significant market expansion beyond therapeutics into diagnostic biomarkers. Additionally, targeted toxins leveraging SV2A internalization are being explored for neuromuscular disorders.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Modulators | UCB Pharma (Brivaracetam), Generic Manufacturers | Epilepsy, Status Epilepticus | Native Conformation Binding (Need Full-Length Lentivirus Cell Lines) |
| PET Imaging Tracers | Yale University, UC Berkeley | Alzheimer's Disease (Synaptic Density) | High-Affinity Binding Assay (Need Purified SV2A Standards) |
| Next-Gen Selective Ligands | Sunovion, Academic Consortia | Refractory Epilepsy | SV2B/C Counter-Screening (Need Paralog Protein Panel) |
| Neuroprotective Biologics | Early-stage Biotech | Traumatic Brain Injury | Cross-Species Reactivity (Need Cyno/Rat Orthologs) |
| Targeted Toxins | Various Institutes | Neuromuscular Disorders | Internalization Assay (Need Native Conformation) |
Clinical Genetics and Mutations
SV2A mutations have been identified in developmental and epileptic encephalopathy type 113 (DEE113). Two notable missense variants include a likely pathogenic mutation (UniProt Q7L0J3 VAR_089450) and a variant of uncertain significance (dbSNP:rs782514088, UniProt VAR_089451). These highlight the role of SV2A in synaptic function and the potential for genotype-guided therapy in epilepsy.